Open Access to Scientific Data & Publications Malcolm Skingle CBE DSc PhD Director – Academic Liaison Westminster Business Forum Drug Discovery 5 th Feb 2013 Royal Society, London
•GSK currently have no formal Position Statement on pre-clinical scientific publication & APCs but support the principle of Open Access to scientific data •GSK share data, reagents & resources with external parties in a bid to expand areas of the science base of value to the whole scientific community •The impact factors for GSK published papers are comparable to those of academia.
Papers with GSK Author 2000-2012 100+ citations Where GSK Authors have contributed to a paper that can be found in Scopus with over 100 citations
Open Innovation - Malaria • Attempts to generate leads vs malaria – GSK screened 2 million compounds vs the malaria parasite P.falciparum to generate 13,500 hits – Took 5 GSK scientists 1 year to complete – GSK to publish the chemical structures & associated assay data – Data freely available via a user-friendly database
EMBL-EBI Database for Mining Malaria Compound Set - www.ebi.ac.uk/chemblntd John Overington, EBI
“Open source” ‐ malaria screening Shared with ~14 groups GSK Malaria Set “TCAMS” MMV Malaria Box Shared with ~100 groups (~50% from TCAMS) 8
Thursday 11 October 2012, London UK GSK announces further initiatives to advance openness and collaboration to help tackle global health challenges • Tuberculosis (TB) ‘compound library’ to be made available to help stimulate research into TB • Investment in GSK’s Tres Cantos Open Lab to be doubled with an additional £5m funding awarded
Concluding Remarks • GSK are changing their internal structures to be more open & transparent with the external science base. • We are keen to share our data with external scientists in order to expand the science base. Open Access publishing is part of this continuum • The more science you share with others, the more you get back from external sources
We are looking for innovation wherever it may originate
Recommend
More recommend
